# Mátyás Keltai

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/matyas-keltai/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,788 |
| Field | Atrial Fibrillation Management and Outcomes |
| h-index | 53 |
| i10-index | 84 |
| OpenAlex ID | https://openalex.org/A5041291525 |
| ORCID iD | https://orcid.org/0000-0002-5465-163X |
| Works | 162 |

## Researcher papers

- [Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind/)
- [Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-stable-cardiovascular-disease/)
- [Initial Invasive or Conservative Strategy for Stable Coronary Disease](https://scholariq.org/papers/initial-invasive-or-conservative-strategy-for-stable-coronary-disease/)
- [Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial](https://scholariq.org/papers/renal-outcomes-with-telmisartan-ramipril-or-both-in-people-at-high-vascular-risk/)
- [Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome](https://scholariq.org/papers/apixaban-with-antiplatelet-therapy-after-acute-coronary-syndrome/)
- [Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-renal-outcomes-in-type-2-diabetes-an-exploratory-analysis-of-the/)
- [Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial](https://scholariq.org/papers/efficacy-of-apixaban-when-compared-with-warfarin-in-relation-to-renal-function/)
- [Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin](https://scholariq.org/papers/safety-of-proton-pump-inhibitors-based-on-a-large-multi-year-randomized-trial-of/)
- [Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study](https://scholariq.org/papers/effect-of-lipid-lowering-therapy-on-early-mortality-after-acute-coronary/)
- [Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial](https://scholariq.org/papers/effect-of-dulaglutide-on-cognitive-impairment-in-type-2-diabetes-an-exploratory/)
- [Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide](https://scholariq.org/papers/design-and-baseline-characteristics-of-participants-in-the-scp-r-scp-esearching/)
- [The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial](https://scholariq.org/papers/the-effect-of-dulaglutide-on-stroke-an-exploratory-analysis-of-the-rewind-trial/)

## Researcher topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.